Login / Signup

The decision to biopsy in a lung cancer screening program: Potential impact of risk calculators.

Christopher R GilbertAlexander S CarlsonCandice L WilshireRalph W AyeAlexander S FarivarAdam J BogradJed A Gorden
Published in: Journal of medical screening (2018)
In our screening program, 5.7% of individuals undergo invasive testing, comparable with the National Lung Screening Trial (6.1%). Both Brock and Mayo calculators perform well in indicating who may be at risk of malignancy, based on clinical and radiologic factors. However, in our invasive testing group, the Brock and Mayo calculators and Lung Cancer Screening Program clinical assessment all lacked clarity in distinguishing individuals who have a cancer from those with a benign abnormality.
Keyphrases
  • quality improvement
  • clinical trial
  • randomized controlled trial
  • squamous cell carcinoma
  • risk assessment
  • open label
  • climate change
  • squamous cell
  • phase ii
  • human health
  • clinical evaluation
  • double blind